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occurred at a rate of 60%, 63%, 67%, 70%, and 90% in AL100, AL20, AL500,
HA, and NS, respectively.
Histology. In the NS group, loss of the superﬁcial layer, ﬁbrillation, and cleft
were observed. In the HA and the AL500 groups, cartilage degeneration
including ﬁbrillation, ﬁssures, and loss of proteoglycan was observed in the
femoral condyle. An obvious reduction in the severity was found in the
AL100 group. The overall degenerative score of the AL100 group tended to
be the lowest, indicating that AL100 suppressed degradation. The overall
scores of the treatment groups were signiﬁcantly lower than that of the NS
group (AL20, AL100, and AL500 vs NS, p<0.01; HA vs NS, p<0.05).
Friction. The friction coeﬃcients of the AL100 and the AL20 group were
signiﬁcantly lower than that of the NS and the HA group (P<0.05).
Table 1. Histological scores and friction coeﬃcient
Histological score Friction coeﬃcient
NS 21.3±1.3 0.0294±0.0014
HA 17.3±1.2 0.0235±0.0013
AL20 14.9±0.9 0.0148±0.0027
AL100 12.6±0.9 0.0122±0.0037
AL500 15.4±0.9 0.0232±0.0117
Conclusions: The current study is the ﬁrst to examine the inﬂuence of
alginate materials on OA progression in vivo. Our ﬁndings suggest that
intraarticular administration of the UPLE-alginates is effective in prevent-
ing articular cartilage degeneration and on improving joint lubrication of
OA knees induced by ACLT. In terms of molecular weight dependency,
AL100 (1.0×106 Da) has more therapeutic effects on OA progression.
Based on these results, we reasonably conclude that the UPLE-alginates,
especially AL100, have promising potential for becoming an effective agent
of intraarticular injection for preventing OA progression.
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Purpose: Viscosupplementation (VS) by intra articular (IA) injection of
hyaluronic acid (HA) is widely used to reduce pain in patients with
knee osteoarthritis (K-OA). However little is known on its effect on joint
metabolism as well as on its possible structure modifying effect. Objectives:
To investigate the effect of VS on circulating OA biomarkers in patients
with K-OA.
Methods: Prospective open label study. 51 patients with unilateral symp-
tomatic K-OA (ACR criteria; Kellgren-Lawrence grade I to IV) received an
IA injection of 2mL of HA (hylan GF-20) IA injection on days (D) 1, 7, 14
and were followed 3 months. At D-15 patients were examined and X-rays
were performed, in order to exclude patients with bilateral K-OA, or those
with more than 3 OA joints including the target knee. From D-15 to D90
concomitant therapies were unchanged. Walking pain (WP) on VAS was
obtained at each visit. Clinical response was deﬁned as a WP decrease >30
mm between D1 and D90 (50% improvement). Urine (U) and serum (S)
samples were obtained, using a standardized procedure, 2 weeks before
the ﬁrst injection (D-15), then at D1 (1st injection), D30 and D90. S-C2C,
S-Cartilage oligomeric protein (S-COMP), S-HA, S-CS846 epitope, S-type II
collagen propeptide (S-PIICP) and U-type II collagen C telopeptide (CTX
II/creatinin) were assayed. Variations over time for each biomarker were
studied using Wilcoxon rank sum test.
Results: 45 patients (mean age 57.7, mean BMI 26.7) were analyzed. At
baseline there was no difference between ITT and per-protocol population.
Between D-15 and D1 there was no signiﬁcant difference for any biomark-
ers (all p>0.05), indicating a good reproducibility in S and U measurements
and the absence of spontaneous variation over time. At D1 WP was
correlated with U-CTX II/creat (p=0.006). Between D1 and D90: Mean (SD)
WP decreased from 57.7 (15.4) to 29.3(22.9) mm (p<0.0001). No variation
was found for any S-biomarker. By contrast U-CTX II/creat was reduced
by 20.5% and decreased signiﬁcantly between D1 and D90 (385.1 vs 306.0
ng/mmol creat; p= 0.02). Furthermore U-CTX II and S-HA levels at baseline
were both but independently predictive of clinical response to treatment
(p=0.03 and p=0.02) even after adjustment for age, gender and BMI. Further
more in logistic regression including age, BMI, bilaterality, KL grade, OA at
other joints, DMOADS consumption and U-CTX II/creat at baseline, there
was a signiﬁcant correlation between clinical response and U-CTX II/creat
level variation (p=0.03).
Conclusions: This study suggests that hylan IA injections are able to mod-
ify the knee joint metabolism in patients with OA resulting in a decrease
in urine CTX II concentrations, particularly in patients with the highest
levels of U-CTX II and HA before treatment. Further studies coupling
biomarkers and imaging techniques are needed to investigate the possible
chondroprotective effect of hylan in K-OA.
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Purpose: VEGF is both a potent angiogenic and vascular permeability factor
that is crucial in endochondral ossiﬁcation involved in bone formation and
remodeling. We hypothesize that osteoarthritis (OA) pain-associated bone
marrow lesions, effusion, and synovitis are in part, driven by VEGF medi-
ated increases in vascular permeability. Soluble fms-link tyrosine kinase 1
(sFlt1), a variant of VEGF receptor Flt1, can potentially block the function of
VEGF. Our previous work demonstrated that VEGF inhibition using virally
delivered sFlt decreased synovitis and pain marker expression in a rabbit
OA model. However, the biological joint half life of recombinant human
sFlt01, a VEGF neutralizing Fc fusion protein, was demonstrated to be just
a few hours. In order to prolong the joint half life of sFlt01, we constructed
a modiﬁed delivery form of this protein, veriﬁed its bioactivity, and con-
ﬁrmed enhanced stability compared to sFlt01 in accelerated stability tests
up to 3 months.
Methods: Modiﬁed sFlt delivery construct TCEP reduction and CuCl2 ox-
idation were used to create a dimerized modiﬁed sFlt delivery construct,
which was subsequently column puriﬁed and compared to native sFlt as
well as the monomer forms of the modiﬁed delivery construct on silver
stained SDS PAGE gels.
In vitro VEGF ELISA binding assay A two-fold serial dilution of sFlt01 or
the modiﬁed sFlt delivery construct starting from 10,000 pM was made
in assay medium (M199 media + 5% FBS + 1x Penn/Strep). VEGF165 (10
pM) was then incubated with the serial dilutions. Unbound VEGF for each
dilution was measured by ELISA to identify whether any shift had occurred
between VEGF neutralization by the modiﬁed sFlt delivery construct vs.
native sFlt01 control.
Accelerated stability test Modiﬁed sFlt delivery construct (0.25 mg/ml)
was incubated in PBS with 1X HALT protease inhibitor cocktail with EDTA
(Pierce) at 45°C and aliquots drawn and ﬂash frozen at -80°C. Unmodiﬁed
sFlt01 at the same concentration was used as a control. The samples were
collected over different time points in both 36 and 94 day stability tests.
The samples with or without PNGase F treatment was further analyzed by
silver-stained reducing SDS PAGE.
Results: TCEP reduction and CuCl2 oxidation resulted in successful dimer-
ization of the modiﬁed sFlt delivery construct.
TCEP reduced protein monomer showed ∼35 fold higher EC50 vs. native
sFlt01 whereas Cu2+ oxidized dimer showed 2.2 - fold high EC50 compared
to sFlt01.
From the accelerated stability test data, sFlt01 control showed increase
amount of ∼35 kDa product as well as high molecular weight of ∼115
kDa product in silver stained reducing SDS PAGE without PNGase treat-
ment. The modiﬁed sFlt delivery construct showed greater stability at
elevated temperature, generating less high molecular weight aggregate and
fragmentation compared to sFlt01 control at both 36 and 96 days.
Conclusion: The generated modiﬁed sFlt delivery construct expressed from
HEK293 can be eﬃciently dimerized.
Copper-generated protein dimer retains high aﬃnity for VEGF binding,
comparable to native sFlt01.
The modiﬁed sFlt delivery construct appears more stable at elevated tem-
